

Oncology studies present specific challenges that generate complex eCOA build and management: complex study design, frequent amendments, and long study duration that can affect patient engagement and site organization.

To overcome these challenges, Kayentis offers strong and global experience in complex oncology trials, especially with:

experienced teams and strong processes to face trial complexities and amendments,

a large set of data collection modes for an optimal data entry,

additional features for the comfort of the patient,

and functionalities adapted to support site staff,

Kayentis contributes to the success and quality of oncology clinical trials.


Learn more in the case study:

**ONCOLOGY CASE STUDY**

# Kayentis

offers global experience in complex  
**oncology trials**

- **65+** studies, 14,000+ patients, 5,000+ sites
- **Large programs**
  - ✓ 90% Global Phase II/III trials across patient populations
  - ✓ 10 to 45 countries per study, worldwide
  - ✓ **Long term studies:** up to 8 years
- **Extensive experience**, including:
  - ✓ CAR-T cell treatment developments
  - ✓ Many indications:
    - ALL, AML, CML, Large B-cell lymphocytic leukemia
    - Follicular lymphoma, myelodysplastic syndrome, multiple myeloma
    - Renal carcinoma, lung, breast, prostate, pancreas, thyroid cancer
    - MTC, Melanoma



**ePRO, eClinRO, eObsRO and eDiary assessment:**  
Many ePROs used to assess disease-related symptoms (eg, pain, fatigue) as well as physical, social & emotional aspects, satisfaction survey:

- **EORTC:** QLQ-C30, QLQ-C31, QLQ-LC13, QLQ-MY20, QLQ-BR23, IL-134, IL-46
- **FACT Fatigue:** FACT-M, FACT-BR, Fact-P, FACT-G, FACT-BMT, FACT -GP5
- **EuroQoL:** EQ-5D 3L/EQ-5D Youth, EQ-5D 5L, PedsQL, young adult & adolescent
- PROMIS-29, PROMIS PSF, PROMIS Parnt Proxy 7
- PRO-CTCAE, MDASI, NSCLC SAQ, PGI-C, PGI-I, PGI-S, NCCN NfBrSI-24

Download the case study  
Contact us for more information

### Key Words:

- eCOA
- ePRO
- eDiary
- oncology
- clinical trial

**Learn more:**



## Rethinking pediatric clinical trials: guidelines from pediatric experts

2 April 2024

In this last episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



## Overcoming challenges in long-lasting pediatric clinical trials – Insights from site experts

26 March 2024

In this third episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)



## Tackling the specificities of NASH/MASH clinical trials

26 March 2024

Integrating PROs into studies on MASH, also known as NASH, is crucial. MASH is a debilitating

[Read More »](#)



## Mastering pediatric asthma clinical trials

19 March 2024

Asthma clinical trials present several specificities, such as the use of disease-specific health-related quality of

[Read More »](#)



## The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs

14 March 2024

NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally

[Read More »](#)



## How DCTs Can Help Pediatric Clinical Research – Insights From Site

---

## Experts

12 March 2024

In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement

[Read More »](#)